Understanding factors influencing primary treatment with intradetrusor onabotulinumtoxinA versus augmentation cystoplasty in patients with spina bifida.

Abstract

PURPOSE:

Surgical interventions in the urologic management of children with neurogenic bladder secondary to spina bifida aim to preserve upper tract function, prevent urinary tract infections, and optimize quality of life. However, since the introduction of intravesical onabotulinumtoxinA (Botox) in the management of these patients, the indications for choosing Botox over augmentation cystoplasty (AC) remain undefined. The objective of this study was to determine which factors lead patients to undergo Botox versus AC as a primary surgical treatment after failing medical management.

METHODS:

We retrospectively reviewed the records of pediatric patients with myelomeningocele undergoing either primary Botox or primary AC at our institution between 2013 and 2018. We recorded demographic and clinical information. We identified 10 important clinical decision-making factors: bladder trabeculation, vesicoureteral reflux, or hydronephrosis on imaging; end-filling pressure (EFP) ≥40 cm H2O, detrusor overactivity, detrusor-sphincter dyssynergia, or reduced capacity on urodynamic studies; physician-perceived bladder hostility; and patient/family desire for continence and independence. The presence of these factors was compared between patients undergoing either primary Botox or primary AC.

RESULTS:

We identified 14 and 50 myelomeningocele patients who underwent primary AC and primary Botox, respectively. We found no significant differences in age, sex, race, or history of reconstructive surgery (antegrade continence enema or catheterizable channel). For the 10 decision-making factors, desire for independence/continence (p = <0.001) and reduced capacity (p = 0.002) were significantly associated with AC, while trabeculation (p = 0.006), EFP ≥40 cm H2O (p = 0.029), rising slope (p = 0.019), and physician-perceived hostility (p = 0.012) were significantly more common with Botox.

CONCLUSIONS:

At our institution, quality of life measures prompted AC over objective urodynamic or imaging findings before attempting Botox. These findings support a shared decision-making approach when considering surgical intervention for neurogenic bladder secondary to myelomeningocele.

• Authors: Belinda Li, Leslie M Peard, Shilin Zhao, M Kyle Graham, Cyrus Adams, Abby S Taylor, John C Thomas, John C Pope, Mark C Adams, John W Brock, Douglass B Clayton
• Journal: Neurourology and urodynamics (Neurourol Urodyn) Vol. 42 Issue 6 Pg. 1431-1436 (08 2023) ISSN: 1520-6777 [Electronic] United States
• PMID: 37249147 (Publication Type: Journal Article)
• Copyright: © 2023 Wiley Periodicals LLC.

Chemical References

• Botulinum Toxins, Type A

Topics

• Humans
• Child
• Urinary Bladder, Neurogenic (drug therapy, etiology, surgery)
• Botulinum Toxins, Type A (therapeutic use)
• Meningomyelocele (complications, surgery)
• Retrospective Studies
• Quality of Life
• Spinal Dysraphism (complications)
• Urodynamics